DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Efficacy and safety of incretinbased therapies: clinical trial data.

Author(s): White J

Affiliation(s): Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WA 99210-1495, USA. whitej@wsu.edu

Publication date & source: 2009-09, J Am Pharm Assoc (2003)., 49 Suppl 1:S30-40.

Publication type: Research Support, Non-U.S. Gov't

OBJECTIVE: Provide a comprehensive overview of efficacy and safety data on incretin-based agents in the treatment of type 2 diabetes. DATA SOURCES: A PubMed search was conducted for the years 2000-2009, using as keywords the names of glucagon-like peptide-1 (GLP-1) receptor agonists (exenatide and liraglutide) and dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, alogliptin, and saxagliptin). World Diabetes Congress abstracts from 2008 to 2009 were also searched for clinical studies of these agents. STUDY SELECTION: The author included randomized controlled trials of incretin therapies that were published in English and enrolled > or =100 participants. DATA EXTRACTION: Data on the effects of incretins on glycemic control, weight, beta-cell function, blood pressure, lipid levels, safety, and tolerability were extracted and summarized. DATA SYNTHESIS: A total of 27 randomized controlled studies of incretin therapy were identified and included in the review. GLP-1 receptor agonists and DPP-4 inhibitors were evaluated at different points in the diabetes treatment spectrum, i.e., added to diet and exercise alone (monotherapy) or added to oral antihyperglycemic regimens (combination therapy). CONCLUSION: In addition to decreasing glycemia in type 2 diabetes, incretin therapies may improve other important parameters, including beta-cell function, blood pressure, and lipid levels, with a low risk for hypoglycemia. A comparison of the study data differentiates the clinical profiles of the GLP-1 receptor agonists, which are associated with weight loss, and DPP-4 inhibitors, which are weight neutral, as well as the individual agents within each class.

Page last updated: 2009-10-20

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017